Azael Freites-Martinez1,2, Donald Chan1, Vincent Sibaud3, Jerry Shapiro4, Gabriella Fabbrocini5, Antonella Tosti6, Juhee Cho7,8, Shari Goldfarb9,10, Shanu Modi9,10, Devika Gajria9,10, Larry Norton9, Ralf Paus6,11, Tessa Cigler10, Mario E Lacouture1. 1. Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Dermatology Service, Hospital Vithas Santa Catalina, Gran Canaria, Canary Islands, Spain. 3. Departments of Oncodermatology and Clinical Research, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France. 4. The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York. 5. Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. 6. Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine Miami, Florida. 7. Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 8. Welch Center for Epidemiology, Prevention, and Clinical Research, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 9. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 10. Department of Medicine, Weill Cornell Medical College, New York, New York. 11. Dermatology Research Centre, University of Manchester, National Institute for Health Research Manchester Biomedical Research Centre, Manchester, United Kingdom.
Abstract
Importance: Persistent alopecia occurs in a subset of patients undergoing chemotherapy, yet the quality of life (QOL) of these patients and their response to therapy have not been described in a large patient cohort. Objective: To characterize the clinical presentation of patients with persistent chemotherapy-induced alopecia (pCIA) or endocrine therapy-induced alopecia after chemotherapy (EIAC) and their QOL and treatment outcomes. Design, Setting, and Participants: A retrospective multicenter cohort of 192 women with cancer treated with cytotoxic agents who received a clinical diagnosis of persistent alopecia (98 with pCIA and 94 with EIAC) between January 1, 2009, and July 31, 2017, was analyzed. All patients were from the dermatology service in 2 comprehensive cancer centers and 1 tertiary-care hospital. Data on demographics, chemotherapy regimens, severity, clinical patterns, and response to hair-growth promoting agents were assessed. Data from the Hairdex questionnaire were used to assess the QOL of patients with alopecia. Main Outcomes and Measures: The clinical presentation, response to dermatologic therapy, and QOL of patients with pCIA were assessed and compared with those of patients with EIAC. Results: A total of 98 women with pCIA (median age, 56.5 years [range, 18-83 years]) and 94 women with EIAC (median age, 56 years [range, 29-84 years]) were included. The most common agents associated with pCIA were taxanes for 80 patients (82%); the most common agents associated with EIAC were aromatase inhibitors for 58 patients (62%). Diffuse alopecia was predominant in patients with pCIA compared with patients with EIAC (31 of 75 [41%] vs 23 of 92 [25%]; P = .04), with greater severity (Common Terminology Criteria for Adverse Events, version 4.0, grade 2) among patients with pCIA (29 of 75 [39%] vs 12 of 92 [13%]; P < .001). A negative emotional effect was reported by both groups. After treatment with topical minoxidil or spironolactone, moderate to significant improvement was observed for 36 of 54 patients with pCIA (67%) and for 32 of 42 patients with EIAC (76%). Conclusions and Relevance: Persistent chemotherapy-induced alopecia is frequently more severe and diffuse when compared with EIAC, and both groups of patients experienced a negative effect. A modest benefit was observed with dermatologic therapy. Additional studies are warranted to develop effective strategies for prevention and effective therapy for pCIA and EIAC.
Importance: Persistent alopecia occurs in a subset of patients undergoing chemotherapy, yet the quality of life (QOL) of these patients and their response to therapy have not been described in a large patient cohort. Objective: To characterize the clinical presentation of patients with persistent chemotherapy-induced alopecia (pCIA) or endocrine therapy-induced alopecia after chemotherapy (EIAC) and their QOL and treatment outcomes. Design, Setting, and Participants: A retrospective multicenter cohort of 192 women with cancer treated with cytotoxic agents who received a clinical diagnosis of persistent alopecia (98 with pCIA and 94 with EIAC) between January 1, 2009, and July 31, 2017, was analyzed. All patients were from the dermatology service in 2 comprehensive cancer centers and 1 tertiary-care hospital. Data on demographics, chemotherapy regimens, severity, clinical patterns, and response to hair-growth promoting agents were assessed. Data from the Hairdex questionnaire were used to assess the QOL of patients with alopecia. Main Outcomes and Measures: The clinical presentation, response to dermatologic therapy, and QOL of patients with pCIA were assessed and compared with those of patients with EIAC. Results: A total of 98 women with pCIA (median age, 56.5 years [range, 18-83 years]) and 94 women with EIAC (median age, 56 years [range, 29-84 years]) were included. The most common agents associated with pCIA were taxanes for 80 patients (82%); the most common agents associated with EIAC were aromatase inhibitors for 58 patients (62%). Diffuse alopecia was predominant in patients with pCIA compared with patients with EIAC (31 of 75 [41%] vs 23 of 92 [25%]; P = .04), with greater severity (Common Terminology Criteria for Adverse Events, version 4.0, grade 2) among patients with pCIA (29 of 75 [39%] vs 12 of 92 [13%]; P < .001). A negative emotional effect was reported by both groups. After treatment with topical minoxidil or spironolactone, moderate to significant improvement was observed for 36 of 54 patients with pCIA (67%) and for 32 of 42 patients with EIAC (76%). Conclusions and Relevance: Persistent chemotherapy-induced alopecia is frequently more severe and diffuse when compared with EIAC, and both groups of patients experienced a negative effect. A modest benefit was observed with dermatologic therapy. Additional studies are warranted to develop effective strategies for prevention and effective therapy for pCIA and EIAC.
Authors: Athina Fonia; Carlo Cota; Jane F Setterfield; Lynne J Goldberg; David A Fenton; Catherine M Stefanato Journal: J Am Acad Dermatol Date: 2017-03-08 Impact factor: 11.527
Authors: Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture Journal: Breast Cancer Res Treat Date: 2018-11-22 Impact factor: 4.872
Authors: Karen E Kinahan; Lisa K Sharp; Kristy Seidel; Wendy Leisenring; Aarati Didwania; Mario E Lacouture; Marilyn Stovall; Anand Haryani; Leslie L Robison; Kevin R Krull Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: Won-Soo Lee; Byung In Ro; Seung Phil Hong; Hana Bak; Woo-Young Sim; Do Won Kim; Jang Kyu Park; Chull-Wan Ihm; Hee Chul Eun; Oh Sang Kwon; Gwang Seong Choi; Young Chul Kye; Tae Young Yoon; Seong-Jin Kim; Hyung Ok Kim; Hoon Kang; Jawoong Goo; Seok-Yong Ahn; Minjeong Kim; Soo Young Jeon; Tak Heon Oh Journal: J Am Acad Dermatol Date: 2007-04-30 Impact factor: 11.527
Authors: Rocío Núñez-Torres; Miguel Martín; Jose Ángel García-Sáenz; María Rodrigo-Faus; María Del Monte-Millán; Hugo Tejera-Pérez; Guillermo Pita; Julio C de la Torre-Montero; Karen Pinilla; Belén Herraez; Lorena Peiró-Chova; Begoña Bermejo; Anna Lluch; Anna González-Neira Journal: JAMA Dermatol Date: 2020-09-01 Impact factor: 10.282
Authors: Gregory S Phillips; Morgan E Freret; Danielle Novetsky Friedman; Sabrina Trelles; Oluwaseun Kukoyi; Azael Freites-Martinez; Robin H Unger; Joseph J Disa; Leonard H Wexler; Christopher L Tinkle; James G Mechalakos; Stephen W Dusza; Kathryn Beal; Suzanne L Wolden; Mario E Lacouture Journal: JAMA Dermatol Date: 2020-09-01 Impact factor: 10.282
Authors: Talveen S Purba; Kayumba Ng'andu; Lars Brunken; Eleanor Smart; Ellen Mitchell; Nashat Hassan; Aaron O'Brien; Charlotte Mellor; Jennifer Jackson; Asim Shahmalak; Ralf Paus Journal: EMBO Mol Med Date: 2019-09-12 Impact factor: 12.137
Authors: Anthony M Rossi; Brian P Hibler; Cristian Navarrete-Dechent; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2020-08-08 Impact factor: 15.487